Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies

Trépo, 2014, Hepatitis B virus infection, Lancet, 384, 2053, 10.1016/S0140-6736(14)60220-8 Jefferies, 2018, Update on global epidemiology of viral hepatitis and preventive strategies, World J Clin Cases, 6, 589, 10.12998/wjcc.v6.i13.589 2022, Hepat B Marcellin, 2013, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, Lancet, 381, 468, 10.1016/S0140-6736(12)61425-1 Papatheodoridis, 2015, Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy, J Hepatol, 62, 956, 10.1016/j.jhep.2015.01.002 Laras, 2006, Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients, Hepatology, 44, 694, 10.1002/hep.21299 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 Lampertico, 2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800 Hall, 2022, Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis, Gut, 71, 1629 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71 Höner Zu Siederdissen, 2016, Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B, J Infect Dis, 214, 1492, 10.1093/infdis/jiw412 Su, 2018, Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy, J Infect Dis, 217, 1193, 10.1093/infdis/jix690 Chi, 2019, Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy, Clin Gastroenterol Hepatol, 17, 182, 10.1016/j.cgh.2018.05.047 Hsu, 2019, Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk, Aliment Pharmacol Ther, 49, 107, 10.1111/apt.15058 Carey, 2020, Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy, Hepatology, 72, 42, 10.1002/hep.31026 Fan, 2020, Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy, Clin Gastroenterol Hepatol, 18, 719, 10.1016/j.cgh.2019.07.046 Fan, 2020, Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B, J Infect Dis, 222, 611, 10.1093/infdis/jiaa136 García-López, 2021, Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients, J Hepatol, 74, 1064, 10.1016/j.jhep.2020.11.043 Kaewdech, 2020, Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation, Liver Int, 40, 2961, 10.1111/liv.14606 Lai, 2020, Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed, JHEP Rep, 2 Liu, 2020, Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy, J Clin Gastroenterol, 54, e73, 10.1097/MCG.0000000000001376 Papatheodoridi, 2020, Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B, J Viral Hepat, 27, 118, 10.1111/jvh.13211 Seto, 2020, Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation, Gut, 70, 775, 10.1136/gutjnl-2020-321116 Tseng, 2020, Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU/mL, Clin Gastroenterol Hepatol, 18, 2803, 10.1016/j.cgh.2020.04.037 Cheng, 2021, Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients, Hepatol Int, 15, 582, 10.1007/s12072-021-10186-7 Huang, 2021, The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients, J Viral Hepat, 28, 1141, 10.1111/jvh.13528 Kuo, 2021, Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation, Hepatol Int, 15, 301, 10.1007/s12072-021-10159-w Liao, 2021, Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B, Int J Gen Med, 14, 4967, 10.2147/IJGM.S321253 Sonneveld, 2022, Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE), Clin Gastroenterol Hepatol, 20, e784, 10.1016/j.cgh.2020.12.005 Wübbolding, 2021, Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB, Hepatol Commun, 5, 97, 10.1002/hep4.1626 Xia, 2021, Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment, Aliment Pharmacol Ther, 54, 709, 10.1111/apt.16538 Xie, 2021, HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation, J Gastroenterol, 56, 856, 10.1007/s00535-021-01812-0 Rinker, 2018, Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B, J Hepatol, 69, 584, 10.1016/j.jhep.2018.05.004 Zimmer, 2018, Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss, J Infect Dis, 217, 1656, 10.1093/infdis/jiy097 Rivino, 2018, Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation, J Clin Invest, 128, 668, 10.1172/JCI92812 Kranidioti, 2019, Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B, J Viral Hepat, 26, 697, 10.1111/jvh.13068 Wu, 2020, Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B, Infect Genet Evol, 78, 10.1016/j.meegid.2019.104124 Xie, 2019, Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term nucleos(t)ide analogue therapy for chronic hepatitis B, BMC Infect Dis, 19, 640, 10.1186/s12879-019-4261-3 Chen, 2022, Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in hepatitis B e Antigen-positive patients, J Infect Dis, 225, 1974, 10.1093/infdis/jiab596 Hall, 2022, Hepatitis B virus flares following nucleot(s)ide analogue cessation are associated with activation of TLR signalling pathways, J Infect Dis, 227, 123, 10.1093/infdis/jiac375 Kaewdech, 2022, Clinical utility of SCALE-B to predict hepatitis B virus relapse, hepatitis B surface antigen loss after antiviral cessation in Asian patients after 2-year follow-up, Front Med (Lausanne), 9 Papatheodoridi, 2022, Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy, J Viral Hepat, 29, 948, 10.1111/jvh.13729 Sonneveld, 2022, Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels, J Hepatol, 76, 1042, 10.1016/j.jhep.2022.01.007 Hsu, 2022, Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort, Hepatol Int, 16, 1297, 10.1007/s12072-022-10411-x Hirode, 2022, Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study), Gastroenterology, 162, 757, 10.1053/j.gastro.2021.11.002 Jeng, 2018, Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B, Hepatology, 68, 425, 10.1002/hep.29640 Chen, 2019, The incidence of hepatitis B surface antigen loss between hepatitis B E antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy, J Infect Dis, 219, 1624, 10.1093/infdis/jiy697 Liang, 2016, Quantitative intrahepatic HBV cccDNA correlates with histological liver inflammation in chronic hepatitis B virus infection, Int J Infect Dis, 52, 77, 10.1016/j.ijid.2016.09.022 Thompson, 2010, Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers, Hepatology, 51, 1933, 10.1002/hep.23571 Rydell, 2022, Abundance of noncircular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients, J Infect Dis, 225, 1982, 10.1093/infdis/jiaa572 Svicher, 2021, Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B, Gut, 70, 2337, 10.1136/gutjnl-2020-323300 Wong, 2007, Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection, J Clin Microbiol, 45, 3942, 10.1128/JCM.00366-07 Prakash, 2018, High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles, Virol J, 15, 86, 10.1186/s12985-018-0994-7 Bertoletti, 2012, Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection, Gut, 61, 1754, 10.1136/gutjnl-2011-301073 Ye, 2015, T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance, Cell Death Dis, 6, e1694, 10.1038/cddis.2015.42 Boni, 2015, Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B, Hepatology, 62, 1697, 10.1002/hep.28155 Burton, 2018, Circulating and intrahepatic antiviral B cells are defective in hepatitis B, J Clin Invest, 128, 4588, 10.1172/JCI121960 Salimzadeh, 2018, PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection, J Clin Invest, 128, 4573, 10.1172/JCI121957 Milich, 1997, Role of B cells in antigen presentation of the hepatitis B core, Proc Natl Acad Sci U S A, 94, 14648, 10.1073/pnas.94.26.14648 Boni, 2012, Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues, Gastroenterology, 143, 963, 10.1053/j.gastro.2012.07.014 Lam, 2017, Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels, Clin Transl Gastroenterol, 8, e125, 10.1038/ctg.2017.51 Jaroszewicz, 2011, Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues, Antivir Ther, 16, 915, 10.3851/IMP1866 Schurich, 2013, The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells, PLoS Pathog, 9, 10.1371/journal.ppat.1003208 Chen, 2020, Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy, Hepatol Int, 14, 317, 10.1007/s12072-019-09991-y Peña-Asensio, 2022, Model to predict on-treatment restoration of functional HBV-specific CD8(+) cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B, Aliment Pharmacol Ther, 55, 1545, 10.1111/apt.16850 Liu, 2014, Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection, PLoS Pathog, 10, 10.1371/journal.ppat.1003856 van Bommel, 2021, Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B, Hepatol Commun, 5, 1632, 10.1002/hep4.1708 Michler, 2020, Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice, Gastroenterology, 158, 1762, 10.1053/j.gastro.2020.01.032 Agarwal, 2022, A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV 'cure, J Hepatol, 77, 245, 10.1016/j.jhep.2022.03.006 Tseng, 2023, Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis, JHEP Rep, 5 Mak, 2023, Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B, Clin Mol Hepatol, 29, 146, 10.3350/cmh.2022.0172 Gehring, 2022, Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection, J Hepatol, 77, 525, 10.1016/j.jhep.2022.02.020 Gill, 2019, Fine needle aspirates comprehensively sample intrahepatic immunity, Gut, 68, 1493, 10.1136/gutjnl-2018-317071 Cornberg, 2020, Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference, J Hepatol, 72, 539, 10.1016/j.jhep.2019.11.003